FDA Cosmetics Director: ‘Sporadic’ WEN AERs Make Case For Mandatory Reporting

In a Q&A posting, FDA Office of Cosmetics and Colors Director Linda Katz offered perspective on how the division handles adverse event reports and makes a case for mandatory AE reporting. She also explains how FDA reacted when WEN-related AERs began rolling in.

Linda Katz
Office of Cosmetics and Colors Director Linda Katz

More from United States

More from North America